|
Strong Pre-Launch Customer Demand Highlights Growing Need for AI Inference Services
DENVER, June 4, 2026 /PRNewswire/ -- SuperX AI Technology Limited ("SuperX" or the "Company"), a full-stack AI infrastructure solutions provider, today announced the launch of its first U.S. AI Inference Cloud Hub (the "Denver Hub") in Denver, Colorado, marking the Company's first operational cloud deployment in North America and an important milestone in its international growth strategy.
Ahead of launch, AI-focused technology companies have reserved a significant portion of the Denver Hub's initial inference capacity, reflecting increasing demand for dedicated AI inference services across a growing range of AI-powered applications.
Powered by NVIDIA AI accelerator technologies, the Denver Hub is designed to deliver high-performance, low-latency, and reliable AI inference services for enterprise customers. Built on SuperX's capabilities in GPU resource orchestration, elastic cloud infrastructure, system-level optimization, and rapid deployment, the platform supports a wide range of AI workloads while remaining compatible with current and future NVIDIA computing platforms. As organizations expand their AI initiatives, the Denver Hub provides a scalable and resilient foundation for the deployment and operation of AI services.
"The AI industry is entering a new phase where success is increasingly defined by the ability to operate AI services reliably and efficiently at scale," said Kenny Sng, Chief Technology Officer of SuperX. "The strong customer reservations we saw before launch reinforce the demand for purpose-built AI inference infrastructure. By combining NVIDIA AI accelerator technologies with SuperX's full-stack infrastructure capabilities, we are helping enterprises deploy and operate AI services more effectively as they scale their AI initiatives."
Strategically located in Denver, the Denver Hub provides connectivity across major North American markets and supports a wide range of AI-driven applications. To accommodate different deployment requirements, SuperX offers both "On-Demand" and "Reserved Capacity" models, giving customers the flexibility to align infrastructure usage with their operational needs.
The launch of the Denver Hub strengthens SuperX's ability to serve customers in North America while extending its international service capabilities. As demand for AI services continues to evolve, the Company will continue evaluating opportunities to enhance its infrastructure capabilities in support of customers across key global markets.
Currently available through an invitation-only onboarding program, the SuperX AI Cloud Platform provides organizations with access to high-performance AI compute resources and enterprise AI deployment solutions. Interested customers can learn more at aicloud.superx.sg.
About SuperX AI Technology Limited (NASDAQ: SUPX)
SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit www.superx.sg.
Safe Harbor Statement
This press release may contain forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.
Forward-looking statements are only predictions. The reader is cautioned not to rely on these forward-looking statements. The forward-looking events discussed in this press release, including delivery schedules, production capacity, and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Follow our social media:
X.com: https://x.com/SUPERX_AI_
LinkedIn: https://www.linkedin.com/company/superx-ai
Facebook: https://www.facebook.com/people/Super-X-AI-Technology-Limited/61578918040072/#
Strong Pre-Launch Customer Demand Highlights Growing Need for AI Inference Services
DENVER, June 4, 2026 /PRNewswire/ -- SuperX AI Technology Limited ("SuperX" or the "Company"), a full-stack AI infrastructure solutions provider, today announced the launch of its first U.S. AI Inference Cloud Hub (the "Denver Hub") in Denver, Colorado, marking the Company's first operational cloud deployment in North America and an important milestone in its international growth strategy.
Ahead of launch, AI-focused technology companies have reserved a significant portion of the Denver Hub's initial inference capacity, reflecting increasing demand for dedicated AI inference services across a growing range of AI-powered applications.
Powered by NVIDIA AI accelerator technologies, the Denver Hub is designed to deliver high-performance, low-latency, and reliable AI inference services for enterprise customers. Built on SuperX's capabilities in GPU resource orchestration, elastic cloud infrastructure, system-level optimization, and rapid deployment, the platform supports a wide range of AI workloads while remaining compatible with current and future NVIDIA computing platforms. As organizations expand their AI initiatives, the Denver Hub provides a scalable and resilient foundation for the deployment and operation of AI services.
"The AI industry is entering a new phase where success is increasingly defined by the ability to operate AI services reliably and efficiently at scale," said Kenny Sng, Chief Technology Officer of SuperX. "The strong customer reservations we saw before launch reinforce the demand for purpose-built AI inference infrastructure. By combining NVIDIA AI accelerator technologies with SuperX's full-stack infrastructure capabilities, we are helping enterprises deploy and operate AI services more effectively as they scale their AI initiatives."
Strategically located in Denver, the Denver Hub provides connectivity across major North American markets and supports a wide range of AI-driven applications. To accommodate different deployment requirements, SuperX offers both "On-Demand" and "Reserved Capacity" models, giving customers the flexibility to align infrastructure usage with their operational needs.
The launch of the Denver Hub strengthens SuperX's ability to serve customers in North America while extending its international service capabilities. As demand for AI services continues to evolve, the Company will continue evaluating opportunities to enhance its infrastructure capabilities in support of customers across key global markets.
Currently available through an invitation-only onboarding program, the SuperX AI Cloud Platform provides organizations with access to high-performance AI compute resources and enterprise AI deployment solutions. Interested customers can learn more at aicloud.superx.sg.
About SuperX AI Technology Limited (NASDAQ: SUPX)
SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit www.superx.sg.
Safe Harbor Statement
This press release may contain forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.
Forward-looking statements are only predictions. The reader is cautioned not to rely on these forward-looking statements. The forward-looking events discussed in this press release, including delivery schedules, production capacity, and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur.
Follow our social media:
X.com: https://x.com/SUPERX_AI_
LinkedIn: https://www.linkedin.com/company/superx-ai
Facebook: https://www.facebook.com/people/Super-X-AI-Technology-Limited/61578918040072/#
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
SuperX Launches First U.S. AI Inference Cloud Hub, Strengthening North American AI Service Capabilities
|
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
OXFORD, United Kingdom and HOUSTON, June 5, 2026 /PRNewswire/ -- Optellum, a leader in AI-enabled lung cancer diagnostics, today announced that it has surpassed 250 clinical sites and analyzed more than 3 million cases to date. This milestone underscores Optellum's commitment to empowering health systems and clinical care teams with the tools needed to identify, prioritize, and manage high-risk lung nodules more effectively. This commercial momentum is supported by first-of-their-kind partnerships across major markets, including with Bristol Myers Squibb in the US, and with the NHS and Intuitive Surgical to support end-to-end AI & robot lung cancer pathways in the UK. It is also reflected in established and new customer deployments at leading health systems, including the University of Pennsylvania Health System, Vanderbilt University Medical Center, and Oxford University Hospitals.
The scale of Optellum's impact is accelerating rapidly, and the company is now helping one patient every 14 seconds. Optellum pioneered the world's first FDA-cleared, CE-marked, and Medicare-reimbursed AI solution for image-based lung cancer risk stratification – Lung Cancer Prediction (LCP) AI, under the CPT codes 0721T and 0722T. LCP AI is helping to reduce the uncertainty associated with indeterminate lung nodules, ensuring that no nodule patient is left behind. Further, the wraparound Virtual Nodule Clinic (VNC) solution supports guideline-aligned decisions and has been shown to improve clinicians' efficiency while reducing time to recommended treatment.[1]
This growth reflects a broader shift toward the adoption of evidence-based innovation in thoracic care. Optellum continues to expand LungOSⓇ, its end-to-end AI-powered lung health platform, powered by the world's first Thorax CT Foundation Model built for real-world precision lung care. This foundation model is the only model in the world to leverage DART, the world's largest lung cancer CT dataset. LungOSⓇ brings VNC together with modules for triage and detection,[2] diagnostic support,[3] and therapy guidance.[4] Looking ahead, Optellum is poised to expand its clinical suite with the upcoming European launch of LungDetect, an exciting addition designed to simplify and accelerate nodule identification and characterization.
"Optellum is incredibly proud to be helping more health systems and clinicians provide timely, life-saving care to a growing number of patients," said Dr. Johnathan Watkins, Optellum's CEO. "Reaching 250 sites and analyzing millions of cases each year is a testament to the dedication of our team and the trust of our clinical partners. However, we are just getting started; we continue to build LungOSⓇ into the must-have "operating system" for lung cancer and thoracic care more broadly. We invite the global healthcare community to join us on our mission to help solve lung cancer by ensuring early diagnosis and early intervention become the standard for everyone everywhere."
Results from Optellum's continued growth and real-world clinical use will continue to be shared with clinicians, healthcare leaders, and policymakers to reach the broader goal of improving outcomes for every thoracic care team, in every hospital, for every patient.
About Optellum
Optellum is a commercial-stage AI healthcare company dedicated to revolutionizing early diagnosis and treatment of lung disease, starting with one of the deadliest, lung cancer.
Optellum is building LungOSⓇ, the end-to-end AI-powered platform for thoracic care. Its flagship product, Virtual Nodule Clinic (VNC) with Lung Cancer Prediction AI (LCP), is the world's first FDA-cleared and reimbursed software-as-a-medical-device (SaMD) solution for AI-powered lung cancer prioritization and diagnostic support. Clinicians trust the Optellum solution to aid them in making the most appropriate life-saving treatment decisions for their patients. Backed by real-world clinical evidence, Optellum's solution accelerates the diagnostic care pathway by enabling early patient identification, enhancing prioritization, and improving clinicians' efficiency, reducing time to guideline-recommended treatment. Optellum VNC is FDA cleared, CE-MDR marked, UKCA marked, and TGA-approved.
Optellum is headquartered in Oxford, UK, and has an office in Houston, Texas, US.
[1] Hill NR et al. Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study. BMJ Open Respiratory Research. 2025;12: e003225. https://doi.org/10.1136/bmjresp-2025-003225
[2] Both text-based detection with Patient Discovery and Patient Safety Net as well as image-based detection. Product availability depends on your region, please contact Optellum for more information.
[3] Commercially available in the US, EU/UK, and Australia.
[4] Pending; for research use only
Media Contact
marketing@optellum.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Optellum Celebrates Accelerating Impact in Lung Cancer Care; Now at Over 250 Sites and Growing
